High RNA-Binding Motif Protein 3 (RBM3) Expression is Independently Associated with Prolonged Overall Survival in Intestinal-Type Gastric Cancer

Ye, Fangpeng; Jin, Peisheng; Cai, Xiaoniao; Cai, PeiPei; Cai, Huimin

doi:10.12659/msm.905314

Cited by 21 publications

(19 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study by Karnevi et al, RBM3 was found to promote periampullary adenocarcinoma, including pancreatic cancer and to be associated with a poor prognosis of patients (27). However, a high level of RBM3 has also been reported to be associated with an improved survival and the decreased expression of RBM3 has been shown to be associated with tumor progression and a poor prognosis of patients with intestinal-type gastric cancer (28), testicular non-seminomatous germ cell cancer (29), esophageal and gastric adenocarcinoma (20), epithelial ovarian cancer (11), urothelial bladder cancer (14) and malignant melanoma (8). These studies demonstrate the tissue specificity of RBM3 in different types of human cancer.…”

Section: Discussionmentioning

confidence: 98%

RBM3 upregulates ARPC2 by binding the 3'UTR and contributes to breast cancer progression

et al. 2019

View full text Add to dashboard Cite

Breast cancer is one of the most common types of cancers which results in a high mortality rate for patients worldwide. In this study, we performed systematical experiments including tissue analysis (immunohistochemistry etc.) and cell functional experiments (cell counting assay, MTT assay, cell colony formation, cell migration assay, cell invasion assay etc.). We demonstrated that the expression level of RNA binding motif protein 3 (RBM3) was higher in human breast cancer tissues compared with adjacent non-tumor tissues. A high level of RBM3 was associated with worse post-operative relapse-free survival (RFS) and overall survival (OS) rates in patients with breast cancer. Among the patients with breast cancer, the expression of RBM3 was associated with patient lymph node metastasis and a high tumor grade. The knockdown of RBM3 markedly decreased the proliferation and metastasis of human breast cancer cells. In downstream pathway analysis, actin related protein 2/3 complex subunit 2 (ARPC2) was determined to be positively regulated by RBM3 through a post-transcriptional 3'UTR-binding manner. ARPC2 also played an oncogenic role and mediated the promoting role of RBM3 in the proliferation and metastasis of human breast cancer cells. Thus, on the whole, the findings of this study demonstrate that RBM3 acts as an oncogene in human breast cancer cells and that the functional depletion of RBM3 may be considered as a potential method for breast cancer therapy.

show abstract

Section: Discussionmentioning

confidence: 98%

RBM3 upregulates ARPC2 by binding the 3'UTR and contributes to breast cancer progression

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The fact that the association with good prognosis was stronger than with temperature itself suggests the involvement of RBM3 in other neuroprotective mechanisms independent of body temperature. High RBM3 levels have been clinically associated with prolonged overall survival in intestinal-type gastric cancer ( Ye et al , 2017 ), good prognosis in invasive breast cancer ( Kang et al , 2018 ) and colon cancer ( Jang et al , 2017 ), and improved response and survival in metastatic colorectal cancer ( Siesing et al , 2017 ), none of which benefits appear temperature-related.…”

Section: Discussionmentioning

confidence: 99%

Cold stress protein RBM3 responds to hypothermia and is associated with good stroke outcome

Ávila‐Gómez

Vieites‐Prado

Dopico-López

et al. 2020

Brain Communications

View full text Add to dashboard Cite

RNA-binding motif protein 3 (RBM3) is a molecular marker of hypothermia that has proved neuroprotective in neurodegenerative disease models. However, its relationship to the well-recognized therapeutic effect of hypothermia in ischemic stroke had not been studied. In this work, the expression of RBM3 was investigated in ischemic animal models subjected to systemic and focal brain hypothermia, specifically the effects of RBM3 silencing and overexpression on ischemic lesions. Moreover, the association of RBM3 levels with body temperature and clinical outcome was evaluated in two independent cohorts of acute ischemic stroke patients (n = 215); these levels were also determined in a third cohort of 31 patients derived from the phase III EuroHYP-1 trial of therapeutic cooling in ischemic stroke. The preclinical data confirmed the increase of brain RBM3 levels in ischemic animals subjected to systemic and focal hypothermia; this increase was selectively higher in the cooled hemisphere of animals undergoing focal brain hypothermia, thus confirming the direct effect of hypothermia on RBM3 expression, while RBM3 up-regulation in ischemic brain regions led to functional recovery. Clinically, patients with body temperature <37.5 °C in the first two cohorts had higher RBM3 values at 24 hours and good outcome at 3 months post-ischemic stroke, while RBM3 levels in the cooled third cohort tended to exceed those in placebo-treated patients. These results make RBM3 a molecular marker associated with the effect of hypothermia in ischemic stroke and suggest its potential application as a promising protective target.

show abstract

“…In contrast, RBM3 downregulation decreases HCT116 colon adenocarcinoma cell proliferation (Sureban et al, 2008). There is an association between RBM3 and more favorable clinic pathological parameters, the higher RBM3 expression, the higher the disease-free survival (DFS) rate is, particularly in patients who received first line oxaliplatin-based chemotherapy (Jones et al, 2014; Venugopal et al, 2016; Jang et al, 2017; Liu Y. et al, 2017; Siesing et al, 2017; Ye et al, 2017).…”

Section: Rbm3mentioning

confidence: 99%

Post-transcriptional Regulation of Colorectal Cancer: A Focus on RNA-Binding Proteins

García-Cárdenas

Guerrero

López‐Cortés

et al. 2019

Front. Mol. Biosci.

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a major health problem with an estimated 1. 8 million new cases worldwide. To date, most CRC studies have focused on DNA-related aberrations, leaving post-transcriptional processes under-studied. However, post-transcriptional alterations have been shown to play a significant part in the maintenance of cancer features. RNA binding proteins (RBPs) are uprising as critical regulators of every cancer hallmark, yet little is known regarding the underlying mechanisms and key downstream oncogenic targets. Currently, more than a thousand RBPs have been discovered in humans and only a few have been implicated in the carcinogenic process and even much less in CRC. Identification of cancer-related RBPs is of great interest to better understand CRC biology and potentially unveil new targets for cancer therapy and prognostic biomarkers. In this work, we reviewed all RBPs which have a role in CRC, including their control by microRNAs, xenograft studies and their clinical implications.

show abstract

High RNA-Binding Motif Protein 3 (RBM3) Expression is Independently Associated with Prolonged Overall Survival in Intestinal-Type Gastric Cancer

Cited by 21 publications

References 31 publications

RBM3 upregulates ARPC2 by binding the 3'UTR and contributes to breast cancer progression

RBM3 upregulates ARPC2 by binding the 3'UTR and contributes to breast cancer progression

Cold stress protein RBM3 responds to hypothermia and is associated with good stroke outcome

Post-transcriptional Regulation of Colorectal Cancer: A Focus on RNA-Binding Proteins

Contact Info

Product

Resources

About